Company intelligence / Profile preview
DanDrit Biotech USA, Inc.
New York City, New York, United Statespmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Phase 3
01
Overview
DanDrit Biotech was a biopharmaceutical company focused on developing dendritic cell-based immunotherapies for cancer. Its lead candidate MelCancerVac targeted the MAGE-A antigen family using autologous dendritic cells loaded with allogeneic tumor lysate. The company expanded its pipeline through acquisitions—including OncoSynergy’s anti-CD29 mAb OS2966 for glioblastoma/ovarian cancer and later Enochian’s HIV/AIDS gene therapy assets. After acquiring Enochian in February 2018, the combined entity rebranded as Enochian BioSciences and shifted focus to advanced gene/cell therapies for oncology and infectious diseases.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Dendritic cell-based immunotherapies/vaccinesMonoclonal antibodiesCell and gene therapiesAI-driven diagnostics and multiomics platforms
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
Request access →03
Partnerships
University of California San Francisco (academic collaboration via OncoSynergy asset purchase)University of Strasbourg (academic collaboration via OncoSynergy asset purchase)Weird Science LLC (exclusive license for HIV technologies post-Enochian merger)
Beyond the preview
Go deeper on DanDrit Biotech USA, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DanDrit Biotech USA, Inc..